Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 14, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 200,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,499.5 pence per share; lowest price paid was 1,491 pence per share.
- Treasury Holdings (Settled): 496,061,327 shares (9.18% of total issued share capital).
- Treasury Holdings (Including Unsettled): 496,961,327 shares (10.13% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,519,571 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 200,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.13% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,907,519,571) to calculate individual ownership percentages under Disclosure and Transparency Rules.
- Confirm the total Treasury share count (496,961,327) representing 10.13% of voting rights.
- Note that the repurchase price ranged between 1,491 pence and 1,499.5 pence per share.